PhaseBio Pharmaceuticals Inc
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2018 | $26 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Jan 2017 | $7 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Feb 2015 | $21 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2009 | $49 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
PhaseBio Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Sep 2018).
SEC Form D · Sep 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2018
That is all the official record says: PhaseBio Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Astrazeneca PLC | Company | not stated | not stated | Held Series C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Catalysta Ventures, LLC | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Hatteras Venture Advisors III, LLC | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Hatteras Venture Affiliates III Lp | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Hatteras Venture Partners I, LP | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Hatteras Ventures Partners III LP | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Peter Justin Klein | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Susan Elizabeth Arnold | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2018) | SEC Form 3 |
| Venture Capital Multiplier Fund | Venture capital | not stated | not stated | Held Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Zeneca, Inc. | Company | not stated | not stated | Held Series C-1 and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John Sharp | Executive officer | Sep 2018 |
| Jonathan Mow | Executive officer | Sep 2018 |
| Joel Sussman | Executive officer | Jul 2015 |
| Ashutosh Chilkoti | Executive officer | Jun 2012 |
| Christopher Prior | Executive officer | Jun 2012 |
| Thomas K Laundon | Executive officer | Jan 2010 |
| Bibhash Mukhopadhyay | Director | Sep 2018 |
| Caroline Loewy | Director | Sep 2018 |
| Clay Thorp | Director | Sep 2018 |
| Jonathan Mow | Director | Sep 2018 |
| Justin Klein | Director | Sep 2018 |
| Linda Tufts | Director | Sep 2018 |
| Nancy Hutson | Director | Sep 2018 |
| Tyrell Rivers | Director | Sep 2018 |
| Ashutosh Chilkoti | Director | Jan 2017 |
| Asish K. Xavier | Director | Jan 2017 |
| Guy K. Fish | Director | Jan 2017 |
| James K. Barrett | Director | Jan 2017 |
| Justin K. Klein | Director | Jan 2017 |
| Michael K. Gutch | Director | Jan 2017 |
| Robert K. Ingram | Director | Jan 2017 |
| Asish K Xavier | Director | Jun 2012 |
| Christopher Prior | Director | Jun 2012 |
| Craig K Rosen | Director | Jun 2012 |
| Guy K Fish | Director | Jun 2012 |
| James K Barrett | Director | Jun 2012 |
| Justin K Klein | Director | Jun 2012 |
| Robert K Ingram | Director | Jun 2012 |
| Ashutosh K Chilkoti | Director | Jan 2010 |
| Clay K Thorp | Director | Jan 2010 |
| Douglas K Reed | Director | Jan 2010 |